公开(公告)号：US20230122228A1

公开(公告)日：2023-04-20

申请号：US17720603

申请日：2022-04-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Matthew C. Rhodes ,  Joseph D. Panarese ,  Samuel Bartlett ,  Wei Li ,  Hui Cao ,  Jiajun Zhang ,  Xiaowen Peng ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14 ,  A61P11/00 ,  A61K9/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220380377A1

公开(公告)日：2022-12-01

申请号：US17735203

申请日：2022-05-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jiajun Zhang ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D487/08 ,  C07D498/18

Abstract: The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11339170B1

公开(公告)日：2022-05-24

申请号：US17479455

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri Gao ,  Wei Li ,  Jiajun Zhang ,  Xiaowen Peng ,  Hui Cao ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12145942B2

公开(公告)日：2024-11-19

申请号：US18130641

申请日：2023-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Jiajun Zhang ,  Xuechao Xing ,  Matthew C. Rhodes ,  Xuri Gao ,  Wei Li ,  Yat Sun Or

IPC: C07D487/10

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240132512A1

公开(公告)日：2024-04-25

申请号：US18377105

申请日：2023-10-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Joseph Helble ,  Anthony Toto ,  Jiajun Zhang ,  George G. Wu ,  Yat Sun Or

IPC: C07D487/10 ,  A61K31/407

CPC classification number: C07D487/10 ,  A61K31/407 ,  C07B2200/13

Abstract: The present invention features crystalline forms of Compound I,




including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.

公开(公告)号：US12006291B2

公开(公告)日：2024-06-11

申请号：US18095155

申请日：2023-01-10

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Jiajun Zhang ,  Hui Cao ,  Ruichao Shen ,  Guoqiang Wang ,  George G. Wu ,  Yat Sun Or

IPC: C07D209/42

CPC classification number: C07D209/42

Abstract: The present invention relates to processes for preparing a Compound (1):




or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.

公开(公告)号：US20230234922A1

公开(公告)日：2023-07-27

申请号：US18095155

申请日：2023-01-10

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Jiajun Zhang ,  Hui Cao ,  Ruichao Shen ,  Guoqiang Wang ,  George G. Wu ,  Yat Sun Or

IPC: C07D209/42

CPC classification number: C07D209/42

Abstract: The present invention relates to processes for preparing a Compound (1):




or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.

公开(公告)号：US20230151019A1

公开(公告)日：2023-05-18

申请号：US17983501

申请日：2022-11-09

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Wei Li ,  Xuri Gao ,  Jiajun Zhang ,  Xiaowen Peng ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

CPC classification number: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11472808B2

公开(公告)日：2022-10-18

申请号：US16892464

申请日：2020-06-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Xiaowen Peng ,  Wei Li ,  Xuri Gao ,  Jorden Kass ,  Byung-Chul Suh ,  Hui Cao ,  Jiajun Zhang ,  Yat Sun Or

IPC: A61K31/519 ,  C07D487/04 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention discloses substituted pyrrolo[1,2-c]pyrimidines, such as the compound which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11352363B1

公开(公告)日：2022-06-07

申请号：US17479530

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Xuri Gao ,  Ruichao Shen ,  Yong He ,  Jiajun Zhang ,  Joseph D. Panarese ,  Hui Cao ,  Xuechao Xing ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.